
Selection and Development of a Lead Biologic for Treating Mitochondrial DisordersAward last edited on: 3/25/19
Sponsored Program
STTRAwarding Agency
NIH : NIATotal Award Amount
$241,568Award Phase
1Solicitation Topic Code
-----Principal Investigator
Blake HillCompany Information
Cytegen Corporation
4230 North Oakland Avenue Unit 154
Milwaukee, WI 53211
Milwaukee, WI 53211
(650) 473-0701 |
nfo@cytegen.com |
www.cytegen.com |
Research Institution
Medical College of Wisconsin
Phase I
Contract Number: 1R41AG059530-01Start Date: 6/15/18 Completed: 5/31/19
Phase I year
2018Phase I Amount
$241,568Project Terms:
Affect; age related; Aging; Agonist; Alzheimer's Disease; Automobile Driving; base; Bayesian Analysis; Bezafibrate; Biogenesis; Biological Assay; Blood; Cardiomyopathies; Cells; Chronic progressive external ophthalmoplegia; Clinical; Clinical Trials; cognitive function; Collaborations; Data; Data Set; Defect; Development; Diabetes Mellitus; Disease; DNA biosynthesis; DNA copy number; DNA polymerase gamma; DNA Sequence Alteration; DNA-Directed DNA Polymerase; Dose; Drug Kinetics; early onset; Endogenous Factors; endurance exercise; Engineering; Evaluation; Excision; Exercise; Genes; Genus Hippocampus; Goals; Government; Heart failure; Hereditary Disease; Impairment; improved; Individual; Intervention; Laboratories; Lead; lead candidate; Link; Malignant Neoplasms; Measures; medical schools; Metformin; Methods; Mitochondria; Mitochondrial Diseases; Mitochondrial DNA; mitochondrial dysfunction; mitochondrial fitness; Mitochondrial Proteins; Modeling; Morphology; mouse model; Mus; Muscle; Mutant Strains Mice; Mutation; Nerve Degeneration; Neurodegenerative Disorders; Neuromuscular Diseases; new technology; novel; Parkinson Disease; Pathologic; Pathway interactions; Patients; Peroxisome Proliferator-Activated Receptors; Persons; Pharmacology; Phase; Polymerase; Pre-Clinical Model; Property; Protein Analysis; Protein Engineering; protein expression; Protein Secretion; Proteins; Proteomics; Quality Control; repaired; Respiration; Resveratrol; reverse genetics; sedentary; Serum; SIRT1 gene; Synaptic plasticity; Syndrome; Testing; Therapeutic; Thiazolidinediones; Tissues; Translations; Universities; Wild Type Mouse; Wisconsin; Work;
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00